GENOCEA BIOSCIENCES, INC.

(GNCA)
  Rapport
Vertraagde tijd Nasdaq  -  20/05 22:00:00 CEST
0.2089 USD   -4.92%
05/05Genocea Biosciences, Inc. Rapporteert Winstresultaten voor het Eerste Kwartaal Geëindigd 31 Maart, 2022
CI
29/04GENOCEA BIOSCIENCES, INC. : HC Wainwright herziet opinie en gaat over naar Neutraal
MM
29/04GENOCEA BIOSCIENCES, INC. : Stifel Nicolaus verlaagt advies naar Neutraal
MM
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op GENOCEA BIOSCIENCES, INC.
05/05GENOCEA BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition ..
05/05Genocea Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31..
29/04Top Premarket Decliners
29/04GENOCEA BIOSCIENCES : Initiates Restructuring and Announces Plan to Explore Strategic Alte..
28/04Genocea Announces Plan to Explore Strategic Alternatives
28/04GENOCEA BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Regulation ..
28/04Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives
11/04TRANSCRIPT : Genocea Biosciences, Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 t..
11/04Wall Street Set for Losses, Surging Treasury Yield Fuels Tech Slump
11/04Top Premarket Gainers
11/04GENOCEA BIOSCIENCES : 21st Annual Needham Virtual Healthcare Conference
08/04TRANSCRIPT : Genocea Biosciences, Inc. - Special Call
08/04Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022
08/04Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022
08/04Genocea Biosciences, Inc. Presents Encouraging Initial Data from GEN-011 Phase 1/2a Tri..
07/04GENOCEA BIOSCIENCES : Investor Webinar
04/04Genocea Biosciences to Host Investor Webinar
18/03GENOCEA BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition ..
18/03Genocea Biosciences, Inc. Auditor Raises 'Going Concern' Doubt
16/03GENOCEA BIOSCIENCES : 32nd Annual Oppenheimer Healthcare Conference
14/03Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference
10/03GENOCEA BIOSCIENCES : Provides Fourth Quarter 2021 Corporate Update - Form 8-K
10/03TRANSCRIPT : Genocea Biosciences, Inc., Q4 2021 Earnings Call, Mar 10, 2022
10/03Genocea Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year..
10/03GENOCEA BIOSCIENCES : Q4 Earnings Snapshot
10/03Genocea Provides Fourth Quarter 2021 Corporate Update
10/03NORTH AMERICAN MORNING BRIEFING : Oil Prices Jump, -2-
09/03GENOCEA BIOSCIENCES : Fourth Quarter 2021 Financial Results
08/03Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting
08/03Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting
08/03Genocea Biosciences, Inc. - John Lunger, of Adaptimmune, Joins Genocea Biosciences' Boa..
07/03GENOCEA BIOSCIENCES : John Lunger, of Adaptimmune, Joins Genocea Biosciences' Board of Dir..
07/03GENOCEA BIOSCIENCES, INC. : Change in Directors or Principal Officers, Financial Statement..
07/03John Lunger, of Adaptimmune, Joins Genocea Biosciences' Board of Directors
07/03John Lunger Joins Genocea Biosciences' Board of Directors
03/03Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast
03/03NORTH AMERICAN MORNING BRIEFING : Oil Prices Top -3-
17/02NORTH AMERICAN MORNING BRIEFING : Stock Futures, -2-
16/02GENOCEA BIOSCIENCES : 11th Annual SVB Leerink Global Healthcare Conference
11/02Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference
09/01GENOCEA BIOSCIENCES : H.C. Wainwright BIOCONNECT Virtual Conference
05/01Genocea to Present at Upcoming Investor Conferences
04/01Genocea Biosciences Teams Up with Janssen to Explore Immunogenicity of Neoantigens
04/01GENOCEA BIOSCIENCES : Provides Corporate Update - Form 8-K
04/01GENOCEA BIOSCIENCES, INC. : Entry into a Material Definitive Agreement (form 8-K)
04/01Genocea Biosciences Provides Corporate Update
04/01Genocea Biosciences Provides Corporate Update
04/01Genocea Biosciences, Inc. Enters into an R&D Collaboration and Option Agreement with Ja..
2021GENOCEA BIOSCIENCES : Stifel 2021 Virtual Healthcare Conference
2021Genocea to Present at the Stifel 2021 Virtual Healthcare Conference
2021GENOCEA BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition ..
2021Genocea Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
2021GENOCEA BIOSCIENCES : Q3 Earnings Snapshot
2021TRANSCRIPT : Genocea Biosciences, Inc., Q3 2021 Earnings Call, Oct 28, 2021
2021GEN-011 NEOANTIGEN-TARGETED PERIPHER : 30 a.m. E.T - Form 8-K
2021GENOCEA BIOSCIENCES, INC. : Results of Operations and Financial Condition (form 8-K)
2021Genocea Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
2021Third Quarter 2021 Financial Results
2021GENOCEA BIOSCIENCES : to Host Third Quarter 2021 Corporate Update Conference Call & Webcas..
2021Genocea to Present at Upcoming Conferences
2021GENOCEA BIOSCIENCES : Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Boa..
2021GENOCEA BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
2021Genocea Biosciences, Inc. Appoints Jennifer Herron to Its Board of Directors
2021Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors
2021GENOCEA BIOSCIENCES : H.C. Wainwright 22nd Annual Global Investment Conference (virtual)
2021Genocea to Present at Upcoming Scientific and Investor Conferences
2021GENOCEA BIOSCIENCES : Management's Discussion and Analysis of Financial Condition and Resu..
2021GENOCEA BIOSCIENCES : Q2 Earnings Snapshot
2021TRANSCRIPT : Genocea Biosciences, Inc., Q2 2021 Earnings Call, Jul 29, 2021
2021GENOCEA BIOSCIENCES, INC. : Results of Operations and Financial Condition (form 8-K)
2021Genocea Biosciences, Inc. Reports Earnings Results for the Second Quarter Ended June 30..
2021GENOCEA BIOSCIENCES : Provides Second Quarter 2021 Corporate Update
2021GENOCEA BIOSCIENCES : Second Quarter 2021 Financial Results
2021Genocea to Host Second Quarter 2021 Corporate Update Conference Call & Webcast
2021GENOCEA BIOSCIENCES : Doses First Patient in Phase 1/2a TiTAN Clinical Trial for GEN-011 N..
1  2  3  4  5Volgende
Volgende evenement op GENOCEA BIOSCIENCES, INC.